Latest news

  • 17 May 2019

    Sensorion announces oral presentation at the European Histamine Research Society. Read

  • 15 May 2019

    Sensorion announces the positive Data Safety Monitoring Board (DSMB) review and continuation of the phase 2 clinical trial for SENS-111 in acute unilateral vestibulopathy (AUV). 86 patients enrolled in SENS-111 clinical trial. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more